Increasing access to treatment and diagnostic options through radiopharmaceuticals

With the Evergreen Springfield Facility set to open within the next two months, Evergreen has already begun expansion to build a GMP state-of-the-art alpha emitter production center, …

Serge Lyashchenko is one of the co-founders of Evergreen Theragnostics and a valued advisor, as well as a radio pharmacist at Memorial Sloan Kettering in NYC, specializing in the …

Oct 18, 2024 · SPRINGFIELD, N.J., -- Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, focused on providing additional treatment options for cancer …

Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into Clinic, Prepare First Commercial Launch, and Expand Industry-Leading CDMO …

Under the agreement, Clovis and Evergreen intend to develop radiolabeling chemistry and analytical methods for use in potential future pre-clinical and clinical studies. ‍ ‍

Evergreen Theragnostics, Inc. is committed to improving the available options for cancer patients through radiopharmaceuticals. Our company is engaged in three core areas: Contract …

Over the next months, Evergreen intends to begin registration enabling therapeutic and diagnostic clinical trials for Lutetium-177 (177Lu) EVG321 and Gallium-68 (68Ga) EVG321. If successful, …

From the new facility, Evergreen is ready and able to serve the manufacturing needs of companies developing and commercializing radiopharmaceuticals, from preclinical and early …

Leveraging a fully integrated pipeline, Evergreen does not just develop medicines, we serve patients by bringing our marketed products from our production facilities to our customers. …